Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation (By similarity).. Additionally we are shipping Lrig1 Antibodies (84) and Lrig1 Kits (2) and many more products for this protein.
Showing 6 out of 10 products:
Role of LRIG1 in cancer [review]
LRIG1 expression may represent a barrier to EMT (show ITK Proteins)
LRIG1 role in the atrophic epidermis
Downregulation of LRIG1 expression in oral verrucous carcinoma tissue is reported.
LRIG1, as a negative mediated gene of tumor, can inhibit biological function of PAs (show PASK Proteins) via inhibiting PI3K (show PIK3CA Proteins)/AKT (show AKT1 Proteins) and Ras/Raf (show RAF1 Proteins)/ERK (show EPHB2 Proteins) pathways, and it might be a new target for gene therapy ofPituitary adenomas
LRIG1 and Fascin-1 (show FSCN1 Proteins) were differently expressed in cancer and normal lung tissue in patients with NSCLC, which could be a biomarker for mediastinal lymph node metastasis in NSCLC patients.
Results suggest that the LRIG1could negatively control MRP-1 (show MDM4 Proteins) and the apoptosis to improve the sensitivity of VP16-related chemotherapy.
ERa-dependent expression of LRIG1 dampens ErbB3 (show ERBB3 Proteins) signaling in luminal breast cancer cells, and by blocking ERa activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 (show ERBB3 Proteins) accumulation, enhanced ErbB3 (show ERBB3 Proteins) signaling to cell survival pathways
These findings demonstrate that LRIG1 is an independent prognostic factor in patients with non-small cell lung cancer
LRIG1 expression was associated with pathological type, differentiation status, and stage of Non-small Cell Lung Cancer. The result showed that LRIG1 was an independent prognostic factor for OS of NSCLC patients.
findings reveal a novel and essential role of Lrig1 in regulating morphogenic events that shape the hippocampal circuits and establish that the assembly of TrkB (show NTRK2 Proteins) with Lrig1 represents a key mechanism for understanding how specific neuronal populations expand the repertoire of responses to BDNF (show BDNF Proteins) during brain development
LRIG1+ cells were found to re-populate the neo-epidermis on day 14, suggesting an important homeostatic role of LRIG1 in skin
a subset of human duodenal tumors exhibited features of LRIG1(-/-) adenomas, including loss of LRIG1, gastric metaplasia (MUCIN5AC and MUCIN6), and increased amphiregulin (show AREG Proteins) and Egfr (show EGFR Proteins) activity.
LRIG1 regulates the postnatal development of ICC-DMP and ICC-SMP from smooth muscle progenitors in mice.
Loss of one Apc (show APC Proteins) allele in Lrig1(+) cells results in inducible stem cell-driven model that recapitulates features of familial adenomatous polyposis.
At later stages, Lrig1 expression is sustained in non-sensory tissues, whereas Lrig2 levels are enhanced in neurons and sensory epithelia.
LRIG1 orchestrates corneal-tissue transparency and cell fate during repair via STAT3 (show STAT3 Proteins).
A review summarizes the data that LRIG1 is a ERBB (show EGFR Proteins) negative regulator and tumour suppressor.
LRIG1 Loss of heterozygosity (LOH) is frequent across cancers and its loss is an early event in the development of human squamous carcinomas.
Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation (By similarity).
leucine-rich repeat protein LRIG1
, leucine-rich repeats and immunoglobulin-like domains protein 1
, ortholog of mouse integral membrane glycoprotein LIG-1
, integral membrane glycoprotein